Prashant Kumar

Bringing a molecule like psilocybin or MDMA to the commercial market is unlike any traditional drug development journey. In its guidance document, the FDA is proving a long-awaited regulatory map to describe how developing these drugs mirrors conventional drug development, and where it chart-starts entirely new territory. At their core, psychedelic drug programs are not exempt from the golden standards of modern medicine. The FDA makes it clear that … Read more

Navigating the labyrinth of FDA regulations often feels like learning a highly specialized dialect of a language you only half-understand. With the release of the July 2026 guidance on formal meetings for Over-the-Counter (OTC) monograph drugs, the agency has introduced a brand-new vocabulary of Type X, Y, and Z meetings. While these terms might sound like characters in an … Read more

Have you ever sent a quick note to your doctor through a patient portal and wondered about the voice on the other side? As healthcare digital infrastructure expands, the overwhelming volume of incoming messages is driving massive clinician burnout. In response, health systems are rapidly turning to generative artificial intelligence (AI) to draft replies. But how … Read more

The commercial development of genome-edited (GE) human gene therapies has historically been constrained by the regulatory mandate to treat every single therapeutic asset as an entirely blank slate. This rigid paradigm frequently forced sponsors to expend millions of dollars and precious clinical timelines executing redundant validation and nonclinical testing protocols for highly related platform technologies. However, the FDA’s latest guidance represents a watershed … Read more

The commercialization landscape for cell and gene therapies (CGT) has historically been restricted by rigid regulatory frameworks designed for traditional biologics. Moving a highly volatile, patient-specific autologous therapy or a low-volume orphan gene vector through a conventional Biologics License Application (BLA) path often felt like forcing a square peg into a round hole. However, the FDA’s May … Read more

In the high-stakes world of drug development, traditional standalone clinical trials increasingly feel like running a marathon in heavy boots. Between soaring costs, competitive recruitment landscapes, and the urgent needs of patients, sponsors are desperately seeking more agile ways to innovate. Enter the FDA’s revised draft guidance on Master Protocols, a regulatory milestone designed to turn multi-study complexity into … Read more

In the high-stakes arena of medical device clearance, a single compromised data point can dismantle years of costly research and development. Recent FDA alerts targeting third-party testing laboratories in China have sent shockwaves through the global medtech industry, revealing widespread fabrication of critical performance data. While it is tempting to view these external laboratories as … Read more

The FDA’s newly minted June 2026 guidance, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, reads like a regulatory dream. It outlines a world where a single, stellar trial paired with smart confirmatory evidence can win an approval. But experienced sponsors know that what is penned by leadership at the top of the agency often … Read more

Imagine spending years poured over a breakthrough biological drug, only to have its regulatory approval stalled by a messy spreadsheet. It is a heartbreak that happens far too often in drug development, where life-saving science clashes with rigid data infrastructure. For years, the path to proving a therapeutic protein won’t trigger an unintended immune response in patients has been … Read more

The world of medical innovation moves at a breathtaking pace, yet getting life-saving therapies to the people who need them requires a complex dance between developers and insurers. Healthcare payors and formulary committees have the monumental task of evaluating a continuous stream of clinical data to decide which treatments are covered and at what cost. … Read more